Marin Xavier, MD of the Scripps Health discusses the greatest impact of immune checkpoint inhibitors in hematologic malignancies at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
www.scrippshealth.org/cancer
Management of hematologic and solid tumor malignancies with PD-1 and PD-L1 monoclonal antibodies
Marin Xavier, MD of the Scripps Health discusses the management of hematologic and solid tumor malignancies with PD-1 and PD-L1 monoclonal antibodies at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
www.scrippshealth.org/cancer
Most common adverse events for PD-1 and PD-L1 monoclonal antibodies
Marin Xavier, MD of the Scripps Health discusses the most common adverse events for PD-1 and PD-L1 monoclonal antibodies at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
Real world experience with the novel immune checkpoint inhibitors
Marin Xavier, MD of the Scripps Heal;th discusses her real world experience with the novel immune checkpoint inhibitors at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
Using Biomarkers in Immunotherapy in Head and Neck Cancer.
Tanguy Seiwert, MD of the University of Chicago discusses using biomarkers in Immunotherapy in Head and Neck Cancer at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
www.scrippshealth.org/cancer
Pembrolizumab and nivolumab Immunotherapies Show Efficacy in Head and Neck Cancer
Tanguy Seiwert, MD of the University of Chicago discusses Pembrolizumab and nivolumab Immunotherapies and that they Show Efficacy in Head and Neck Cancer at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
www.scrippshealth.org/cancer
Immunotherapy is well tolerated in Head and Neck Cancer
Tanguy Seiwert, MD of the University of Chicago discusses Immunotherapy and how it is well tolerated in Head and Neck Cancer at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
www.scrippshealth.org/cancer
Immunotherapy and future use of combination treatment in Head and Neck Cancer
Tanguy Seiwert, MD of the University of Chicago discusses immunotherapy and future use of combination treatment in Head and Neck Cancer at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
www.scrippshealth.org/cancer
Venetoclax in the management of CLL and where in the therapeutic algorithm it should play a role
Susan M. O'Brien, MD of University of California Irvine discusses Venetoclax in the management of CLL and where in the therapeutic algorithm it should play a role at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
www.scrippshealth.org/cancer
eferred treatment regimen for patients who fail frontline therapy in CLL
Susan M. O'Brien , MD of University of California Irvine the preferred treatment regimen for patients who fail frontline therapy in CLL at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
www.scrippshealth.org/cancer
Preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab
Susan M. O'Brien, MD of University of California Irvine the preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
www.scrippshealth.org/cancer
Preferred frontline regimen for new CLL patients greater than 70 years
Susan M. O'Brien, MD of University of California Irvine discusses the preferred frontline regimen for new CLL patients greater than 70 years at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
Marin Xavier, MD of the Scripps Health discusses the greatest impact of immune checkpoint inhibitors in hematologic malignancies at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.